Table 2.
Relevant in vitro studies investigating the effects of ADSCs on breast cancer.
| Reference | Year | ADSC origin | ADSC surface marker | BCC line | Effects on BCC |
|---|---|---|---|---|---|
|
Trivanović et al. [58] |
2014 | Human breast (normal versus cancer-affected) and abdominal |
CD44+CD73+CD90+CD105+
CD11a−CD33−CD45−CD235a− HLA-DR−CD34± |
MCF-7 | Proliferation↑ (direct coculture) Proliferation↓ (indirect coculture) Different ADSCs had similar effects |
|
| |||||
| Kucerova et al. [23] |
2013 | Human lipoaspirates | CD29+CD44+CD90+CD105+
CD14−CD34−CD45− |
SKBR3 | Proliferation↓, migration↑ EMT markers↑ BCC chemosensitivity↑ |
|
| |||||
| Lin et al. [46] |
2013 | Human lipoaspirates | CD29+CD44+CD105+
CD31−CD34−HLA-DR− |
MCF-7 | Proliferation and migration↑ Cell-to-cell contact needed Wnt pathway↑ |
|
| |||||
| Strong et al. [72] |
2013 | Human abdominal versus nonabdominal |
n.s. | MCF-7, MDA-MB-231 | Proliferation↑ Leptin/estrogen-dependent Increased effect of abdominal ADSCs from obese (versus lean and nonabdominal ADSCs) |
|
| |||||
| Zhang et al. [50] |
2013 | Human breast (cancer-affected) | CD13+CD29+CD44+CD71+
CD105+HLA-I+ CD4−CD10−CD14−CD34− CD38−HLA-DR− |
MCF-7 | Proliferation↑ Migration↑ |
|
| |||||
| Zhao et al. [47] |
2013 | Human lipoaspirates (abdominal) |
CD29+CD44+CD105+
CD34−CD45− |
MCF-7 | Migration↑ Angiogenesis↓ MMPs↑ |
|
| |||||
| Devarajan et al. [70] |
2012 | Human whole fat |
n.s. | 4T1 (murine) BT-474, MCF-7, T47D |
Proliferation↑, EMT markers↑ PDGF-dependent (paracrine) |
|
| |||||
| Jotzu et al. [109] |
2011 | Human whole fat |
CD29+CD44+CD90+CD105+
CD14−CD34−CD45− |
MCF-7, MDA-MB-231 | Migration and invasion↑ ADSCs differentiate to CAFs |
|
| |||||
| Kucerova et al. [93] |
2011 | Human lipoaspirates | CD44+CD73+CD90+CD105+
CD14−CD34−CD45− |
MCF-7, T47D, MDA-MB-361 | BCC proliferation↑ (dose-dependent) Paracrine mechanism |
|
| |||||
| Razmkhah et al. [61] |
2011 | Human breast (cancer-affected) |
CD44+CD105+CD166+
CD14−CD34−CD45− |
MCF-7 | Anti-inflammatory cytokines↑ T regs↑ |
|
| |||||
| Yan et al. [98] |
2012 | Human breast (normal versus cancer-affected) |
CD29+CD73+CD90+CD105+
CD166+ CD31−CD144−CD14−CD45− HLA-DR− |
MCF-7 | Proliferation↑ (BC ADSCs > normal breast ADSCs) EGF/EGFR/Akt-dependent |
|
| |||||
| Pinilla et al. [38] |
2009 | Human abdominal | n.s. | MDA-MB-231 | Proliferation↑, RANTES↑ Migration↑, MMPs↑ |
|
| |||||
| Welte et al. [73] |
2012 | Human lipoaspirates (abdominal) |
CD44+CD90+CD105+
CD11b−CD14−CD34−CD45− HLA-DR− |
MCF-7, MDA-MB-231, T47D | ADSC migration towards BCCs Migration and invasiveness↑ IL-8↑ |
ADSC: adipose-derived stem cell; BC: breast cancer; BCC: breast cancer cell; CAF: cancer-associated (myo) fibroblast; EMT: epithelial-to-mesenchymal transition; ER: estrogen receptor; Her2: human epidermal growth factor receptor 2; MMPs: matrix metalloproteinases; MPE: metastatic pleural effusion; n.s.: not specified; PR: progesterone receptor; T reg: regulatory T lymphocyte.